tiprankstipranks
Merck KGaA Sponsored ADR (MKKGY)
OTHER OTC:MKKGY
US Market

Merck KGaA Sponsored ADR (MKKGY) Earnings Dates, Call Summary & Reports

4 Followers

Earnings Data

Report Date
May 14, 2026
Before Open (Confirmed)
Period Ending
2026 (Q1)
Consensus EPS Forecast
0.46
Last Year’s EPS
0.47
Same Quarter Last Year
Based on 0 Analysts Ratings

Earnings Call Summary

Q4 2025
Earnings Call Date:Mar 05, 2026|
% Change Since:
|
Earnings Call Sentiment|Neutral
The call presented a mixed but resilient picture: Merck delivered on 2025 guidance, achieved organic EBITDA growth, and showed sector-level recoveries (notably Life Science and semiconductor materials) and strategic progress through M&A and site investments. However, meaningful headwinds remain — significant foreign exchange pressures, the imminent U.S. loss of Mavenclad exclusivity, near-term weakness in the Electronics DS&S business, and regulatory/portfolio uncertainties. Management’s proactive strategic moves and solid cash generation balance these risks, leaving the company positioned for medium-term growth but with clear short-term challenges.
Company Guidance
Merck guided for 2026 to group net sales of EUR 20.0–21.1 billion (organic sales -1% to +2%) and group EBITDA pre of EUR 5.5–6.0 billion, based on three key assumptions: portfolio effects from the SpringWorks acquisition and Surface Solutions divestment (portfolio items to show effects in H1 and contribute organically in H2), no U.S. Mavenclad sales from March 2026 (Mavenclad was ~EUR 1.2 billion in 2025, roughly 50% in the U.S.), and continued negative and volatile FX (with a disproportionate Q1 headwind). Sector guidance: Life Science is expected to deliver mid-single-digit organic growth, Healthcare faces a challenging year with life‑cycle pressure on key brands (notably Mavenclad) but growth in CM&E, fertility and rare‑diseases (rare diseases turning organic in H2), and Electronics should see continued strong growth in semiconductor materials while DS&S stabilizes.
Delivered on Full-Year Guidance
Merck delivered on its 2025 guidance with group net sales around stable at EUR 21.1 billion and group EBITDA pre of EUR 6.1 billion, corresponding to a margin of 28.9%.
Organic EBITDA Growth
Group EBITDA pre grew 5.6% on an organic basis for the full year 2025, indicating profitable growth despite headwinds.
Quarterly Momentum in Q4 2025
Q4 2025 organic group sales grew 2.6% and group EBITDA pre was up 3.1% organically, driven by contributions across all three sectors.
Life Science Recovery and Growth
Life Science returned to organic growth of 4% for 2025, with Process Solutions delivering double-digit organic growth; Life Science EBITDA pre rose 3.9% organically and maintained an EBITDA pre margin of 28.8%.
Strong Healthcare Performance
Healthcare net sales climbed 3.7% organically in 2025. CM&E grew 7% organically, and the sector delivered EBITDA pre of EUR 3.0 billion, up more than 11% organically. Fertility (Pergoveris) and Mavenclad showed double-digit growth in Q4.
Semiconductor Materials Strength in Electronics
Electronics’ semiconductor materials business achieved its strongest quarter in Q4 and delivered high single-digit organic sales growth for the year, benefiting from AI-driven demand and advanced nodes. The EUR 500 million Semiconductor Solutions megasite in Taiwan was inaugurated in December 2025.
Strategic M&A and Portfolio Moves
Completed the acquisition of SpringWorks (adding rare diseases as a strategic growth pillar), acquired Unity-SC (contributed to organic growth), announced sale of Surface Solutions to focus Electronics as a pure-play semiconductor solutions business, and acquired JSR chromatography and HUB Organoids to bolster Life Science capabilities.
Significant Capex and Site Investments
Invested over EUR 7 billion in more than 30 new and expanded sites worldwide in recent years, opened a EUR 100 million facility in Blarney (Ireland), and announced continued region-for-region investments supporting local operations.
Shareholder Return
Board to propose a stable dividend of EUR 2.20 at the Annual General Meeting, reflecting cash generation and capital allocation discipline.

Merck KGaA Sponsored ADR (MKKGY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

MKKGY Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
May 14, 2026
2026 (Q1)
0.46 / -
0.473
Mar 05, 2026
2025 (Q4)
0.46 / 0.43
0.448-2.90% (-0.01)
Nov 13, 2025
2025 (Q3)
0.51 / 0.54
0.48610.70% (+0.05)
Aug 07, 2025
2025 (Q2)
0.50 / 0.47
0.475-1.05% (>-0.01)
May 15, 2025
2025 (Q1)
0.49 / 0.47
0.4475.82% (+0.03)
Mar 06, 2025
2024 (Q4)
0.45 / 0.45
0.40410.89% (+0.04)
Nov 14, 2024
2024 (Q3)
0.49 / 0.49
0.4449.46% (+0.04)
Aug 01, 2024
2024 (Q2)
0.45 / 0.47
0.481-1.25% (>-0.01)
May 15, 2024
2024 (Q1)
0.40 / 0.45
0.515-13.20% (-0.07)
Mar 07, 2024
2023 (Q4)
0.41 / 0.40
0.492-17.89% (-0.09)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

MKKGY Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Mar 05, 2026
$28.64$26.22-8.46%
Nov 13, 2025
$26.83$28.27+5.37%
Aug 07, 2025
$24.54$24.31-0.94%
May 15, 2025
$27.78$25.82-7.04%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Merck KGaA Sponsored ADR (MKKGY) report earnings?
Merck KGaA Sponsored ADR (MKKGY) is schdueled to report earning on May 14, 2026, Before Open (Confirmed).
    What is Merck KGaA Sponsored ADR (MKKGY) earnings time?
    Merck KGaA Sponsored ADR (MKKGY) earnings time is at May 14, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is MKKGY EPS forecast?
          MKKGY EPS forecast for the fiscal quarter 2026 (Q1) is 0.46.